https://go.evvnt.com/974565-0?pid=5248 Embassy Suites by Hilton Boston Logan Airport
207 Porter St
Boston, Massachusetts 02128
Lectures & Conferences
Welcome to the 3rd Annual RNAi - Based Therapeutics Summit: Overcoming Barriers for Targeted siRNA Therapeutics
Built with biopharmaceutical industry insights, this in person conference will bring together key opinion leaders to delve deep into the key remaining challenges associated with targeted delivery, translation, CMC and clinical development of targeted siRNA therapeutics for modular, reproducible and effective gene silencing therapies against oncology, CNS, rare diseases and beyond.
With 28 pioneering speakers from large pharma, innovative biotech and KOLs of academia who are ready to discuss the full and comprehensive range of RNAi drugs from discovery to development and beyond, join us in Boston to hear how they address the major challenges facing the industry.
Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4946.0,
Drug Developer Pricing - Conference Only: USD 2999.0,
Academic and Research Institute Pricing - 3 Day Pass (Conference + Workshop Day): USD 4246.0,
Academic and Research Institute Pricing - Conference Only: USD 2599.0,
Standard Pricing - 3 Day Pass (Conference + Workshop Day): USD 5846.0,
Standard Pricing - Conference Only: USD 3599.0
Speakers: Julia Alterman, Senior Scientist, Khvorova Lab, University of Massachusetts Medical School, Uli Stilz, VP, Novo Nordisk Bio Innovation Hub, Marie Wikstrom Lindholm, SVP and Head of Molecular Design, Silence Therapeutics, David Evans, CSO, Sirnaomics, Ying Yu, Associate Director, AbbVie, Annabelle Biscans, Associate Principal Scientist, AstraZeneca R and D, Tamar Grossman, Global Head of RNA and Targeted Therapeutics, The Janssen Pharmaceutical Companies of Johnson and Johnson, Zdravka Medarova, CTO, TransCode Therapeutics, Guy Hermans, CEO, Sapreme Technologies BV, Robert Shaffer, Founder and COO, Vrata Therapeutics, Ioanna Mylonaki, Head of Preclinical R and D, Sixfold Bioscience, Leonora Abdullahu, Research Scientist, Eli Lilly and Company, Josh Born, Research Scientist, Eli Lilly and Company, Zhanna Druzina, Director, Protein Engineering Aro Biotherapeutics, Cynthia Arbeeny, CSO, Mitotherapeutix, Jeske Smink, Head of Drug Substance, Silence Therapeutics, Dal-Hee Min, CTO and Co-Founder, Lemonex Inc. and Professor, Seoul National University, Naresh Badgujar, Associate Principal Scientist, AstraZeneca, Ulf Landmesser, Medical Director, Charite - Universitatsmedizin Berlin, Steve Stice, Co-Founder and CSO, Aruna Bio, Justin Murray, Director Research, Amgen, Michel Khrestchatisky, Research Director, CNRS, Director, Institute for Neurophysiopathology, Co-Founder and Scientific Counsel, Vect-Horus, Peter Goughnour, Director of R and D, Curigin, Thomas Thum, Professor and Institute Director and CSO and Co - Founder, Hannover Medical School and Cardior Pharmaceuticals, Xiaobo Zhong, Professor of Pharmacology and Toxicology, University of Connecticut, Daniel O'Reilly, Post Doctoral Associate, Khvorova Lab RNA Therapeutics Institute, Vignesh N. Hariharan, Post Doctoral Associate, Khvorova Lab RNA Therapeutics Institute, Qi Tang, Post Doctoral Associate, Khvorova Lab RNA Therapeutics Institute